Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

897
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
897
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

343
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
343
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Culmerciclib: First Approval.

Drugs·2026
Same author

Plozasiran: First Approval.

Drugs·2026
Same author

Puzolcabtagene Autoleucel: Pediatric First Approval.

Paediatric drugs·2026
Same author

Donidalorsen: First Approval.

Drugs·2025
Same author

Viloxazine Extended-Release: A Review in Attention-Deficit/Hyperactivity Disorder in Adults.

CNS drugs·2025
Same author

Lisaftoclax: First Approval.

Drugs·2025
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Related Experiment Video

Updated: May 6, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.6K

Catumaxomab: First Approval.

Yahiya Y Syed1

  • 1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|April 30, 2025
PubMed
Summary
This summary is machine-generated.

Catumaxomab, a bispecific antibody, is approved for malignant ascites in adults with EpCAM+ carcinomas. This therapy targets tumor cells and immune cells, enhancing tumor cell killing via multiple immunological mechanisms.

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.1K
High-Resolution Cardiac Positron Emission Tomography/Computed Tomography for Small Animals
11:09

High-Resolution Cardiac Positron Emission Tomography/Computed Tomography for Small Animals

Published on: December 16, 2022

2.8K

Related Experiment Videos

Last Updated: May 6, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.6K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.1K
High-Resolution Cardiac Positron Emission Tomography/Computed Tomography for Small Animals
11:09

High-Resolution Cardiac Positron Emission Tomography/Computed Tomography for Small Animals

Published on: December 16, 2022

2.8K

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Catumaxomab is a bispecific trifunctional antibody targeting EpCAM on tumor cells and CD3 on T cells.
  • Its Fc domain engages accessory cells, bridging immune and tumor cells to enhance tumor cell killing.
  • Catumaxomab was previously approved for malignant ascites but withdrawn for commercial reasons.

Purpose of the Study:

  • To summarize the development milestones of catumaxomab.
  • To highlight the recent EU reapproval for malignant ascites treatment.

Main Methods:

  • Review of catumaxomab's development history.
  • Analysis of its mechanism of action and previous regulatory status.

Main Results:

  • Catumaxomab received initial EU approval in 2009 for malignant ascites.
  • It was withdrawn in 2017 due to commercial reasons.
  • On February 11, 2025, catumaxomab was reapproved in the EU for intraperitoneal treatment of malignant ascites in specific adult cancer patients.

Conclusions:

  • Catumaxomab's journey illustrates the complexities of drug development and commercialization.
  • The reapproval signifies its continued therapeutic potential in oncology, particularly for malignant ascites.